Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting

Germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Stossel, Chani, Raitses-Gurevich, Maria, Atias, Dikla, Beller, Tamar, Glick Gorman, Yulia, Halperin, Sharon, Peer, Eyal, Denroche, Robert E., Zhang, Amy, Notta, Faiyaz, Wilson, Julie M., O'Kane, Grainne M., Haimov Talmoud, Elina, Amison, Nora, Schvimer, Michael, Salpeter, Seth J., Bar, Vered, Zundelevich, Adi, Tirosh, Itay, Tal, Rotem, Dinstag, Gal, Kinar, Yaron, Eliezer, Yonatan, Ben-David, Uri, Gavert, Nancy S., Straussman, Ravid, Gallinger, Steven J., Berger, Raanan, Golan, Talia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401074/
https://www.ncbi.nlm.nih.gov/pubmed/37449843
http://dx.doi.org/10.1158/2159-8290.CD-22-0412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401074/
https://www.ncbi.nlm.nih.gov/pubmed/37449843
http://dx.doi.org/10.1158/2159-8290.CD-22-0412

Ejemplares similares